Since the development of anti-FIX antibodies significantly affects the safety of the therapeutic protein in hemophilia B patients47, we obtained FIX deficient plasma supplemented with anti-FIX inhibitory antibodies and compared the kinetics of interaction with WT and CO FIX. The gene discussed is F9; the disease is hemophilia B.